Recently, scholars have successively discovered MEK1/2 inhibition (MEKi) (52), DNA methyltransferase 1 (DNMT1) (53), and cytoskeleton-associated protein 4 (CKAP4) (54) and other therapeutic targets for pancreatic cancer, but it still needs further clinical verification. Here, CKAP4 is linked to familial pancreatic carcinoma.